One such example involved a patient who was referred to clinic for uncontrolled depression while taking a CYP2C19-guided SSRI; upon medication reconciliation, the pharmacist learned that the patient was taking a CYP2D6-guided opioid as well. This evidence concerns the gene CYP2C19 and depressive symptom measurement.